[quoteIf the combo works with Keytruda, Merck will will want a BO. What Merck wants Merck will get][/quote]
At 6 months after surgery, the PFS status of recurrent glioblastoma patients receiving the combo treatment as well as those receiving only the autologous dendritic cell lysate vaccine, will be compared to PFS results obtained from external data.
Hopefully the DC vaccine arm will demonstrate a much higher percentage of patients with PFS than the external control data and hopefully the combo arm will demonstrate even better results. That will give Merck something to chew on and at the same time demonstrate the efficacy of DCVax-L.
The capacity to run such a trial indicates that distinguishing progression from pseudo-progression is no longer a major obstacle and therefore such a trial could be initiated in 2021 but not in 2011.
Market Data 
Markets 
AI
